Related Experiment Video
Updated: Mar 9, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.7K
Pioglitazone could induce remission in major depression: a meta-analysis
Romain Colle1, Delphine de Larminat1, Samuel Rotenberg1
1Psychiatry Department, Hôpital Bicêtre, INSERM, UMR S1178, University Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
Neuropsychiatric Disease and Treatment
|December 30, 2016
Summary
Pioglitazone shows promise as an antidepressant, significantly increasing remission rates for major depressive episodes (MDE). This meta-analysis suggests its potential as a clinically relevant antidepressant, even for patients without metabolic issues.
Area of Science:
- Pharmacology
- Neuroscience
- Metabolic Disorders
Background:
- Pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist used for type 2 diabetes, exhibits potential antidepressant properties.
- The efficacy of pioglitazone in inducing remission of major depressive episodes (MDE) requires further investigation, as previous trials yielded mixed results.
- This study addresses the concern regarding pioglitazone's antidepressant potential by focusing on remission rates in MDE.
Purpose of the Study:
- To conduct a meta-analysis evaluating the efficacy of pioglitazone in treating major depressive episodes (MDE).
- To specifically assess the impact of pioglitazone on remission rates in patients with MDE.
- To determine if pioglitazone, alone or as add-on therapy, can achieve higher remission rates compared to control treatments.
Main Methods:
- A meta-analysis included four double-blind randomized controlled trials with 161 patients diagnosed with MDE.
- Pioglitazone was administered as monotherapy or as an add-on to conventional treatments (antidepressants or lithium).
- Comparisons were made against placebo (three studies) or metformin (one study), with remission defined as a Hamilton Depression Rating Scale score <8.
Main Results:
- Pioglitazone demonstrated significantly higher remission rates (27%) compared to control treatments (10%), with an odds ratio (OR) of 3.3 (95% CI [1.4; 7.8], P=0.008).
- In patients with major depressive disorder (MDD) (n=80), pioglitazone showed even higher remission rates (23% vs. 8%, OR=5.9).
- Patients without metabolic comorbidities (n=84) also exhibited improved remission rates with pioglitazone (33% vs. 10%, OR=5.1), suggesting a need to treat six patients for one additional remission.
Conclusions:
- Pioglitazone, as monotherapy or add-on treatment, can effectively induce remission of major depressive episodes (MDE).
- The findings suggest that drugs targeting PPAR-γ agonists may possess true antidepressant properties.
- Pioglitazone's antidepressant potential is evident even in patients without co-existing metabolic comorbidities.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
771
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
771
01:23Dipeptidyl Peptidase 4 Inhibitors
827
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827
01:23Antidepressant Drugs: MAOIs and Other Agents
1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
785
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
785
01:26Psychosis: Goals of Pharmacotherapy
646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646